Heron Therapeutics Appoints CMO
This article was originally published in Scrip
Heron Therapeutics has appointed Neil J. Clendeninn senior vice-president and chief medical officer (CMO). Clendeninn is currently a practicing physician and program director for Palliative Medicine Partners. He is also president of his own consultancy firm CANDAID, Inc and was advisor to the company before joining Heron. Previously, Clendeninn also served as senior vice-president and head of clinical affairs at Agouron Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.